Matinas BioPharma Holdings (MTNB) Other financing activities (2013 - 2025)
Matinas BioPharma Holdings (MTNB) posted quarterly Other financing activities of $27000.0 for Q2 2025, down 99.71% year-over-year from $9.2 million in Q2 2024, and up 1250.0% quarter-over-quarter from $2000.0 in Q1 2025.
Matinas BioPharma Holdings (MTNB) Other financing activities (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Other financing activities for 10 consecutive years, with $27000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Other financing activities fell 99.71% year-over-year to $27000.0; the TTM figure through Dec 2025 stood at $29000.0 (down 99.68% YoY), while the FY2025 annual figure was $29000.0, down 99.68% from the prior year.
- Other financing activities climbed to $27000.0 in Q2 2025 per MTNB's latest filing, from $2000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $9.2 million in Q2 2024 and bottomed at -$4.2 million in Q3 2021.
- Historically, Other financing activities has averaged $1.2 million across 4 years, with a median of $27000.0 in 2025.
- On a YoY basis, Other financing activities climbed as much as 599.67% in 2021 and fell as far as 505.55% in 2021.
- Matinas BioPharma Holdings' Other financing activities stood at $14342.0 in 2021, then jumped by 590.28% to $99000.0 in 2022, then slumped by 165.66% to -$65000.0 in 2024, then surged by 141.54% to $27000.0 in 2025.
- Business Quant data shows MTNB's Other financing activities at $27000.0 in Q2 2025, $2000.0 in Q1 2025, and -$65000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Sep 30, 2024 | -65,000.00 |
| Sep 30, 2024 | -65,000.00 |
| Jun 30, 2024 | 9.19 Mn |
| Jun 30, 2024 | 9.19 Mn |
| Mar 31, 2024 | 54,000.00 |
| Mar 31, 2024 | 54,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Dec 31, 2021 | 14,342.00 |
| Dec 31, 2021 | 14,342.00 |
| Sep 30, 2021 | -4.18 Mn |
| Sep 30, 2021 | -4.18 Mn |
| Mar 31, 2021 | 5.58 Mn |
| Mar 31, 2021 | 5.58 Mn |
| Dec 31, 2020 | 46.60 Mn |
| Dec 31, 2020 | 46.60 Mn |